Cargando…
Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma
PURPOSE: The objective of this retrospective study was to determine the feasibility of measuring frailty using patient responses to relevant EORTC QLQ-C30 items as proxy criteria for the Fried Frailty Phenotype, in a cohort of patients with Relapsed/Refractory Multiple Myeloma (RRMM). METHODS: Data...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025057/ https://www.ncbi.nlm.nih.gov/pubmed/36935467 http://dx.doi.org/10.1007/s11136-023-03390-5 |
_version_ | 1784909242680999936 |
---|---|
author | Murugappan, Meena N. King-Kallimanis, Bellinda L. Bhatnagar, Vishal Kanapuru, Bindu Farley, Joel F. Seifert, Randall D. Stenehjem, David D. Chen, Ting-Yu Horodniceanu, Erica G. Kluetz, Paul G. |
author_facet | Murugappan, Meena N. King-Kallimanis, Bellinda L. Bhatnagar, Vishal Kanapuru, Bindu Farley, Joel F. Seifert, Randall D. Stenehjem, David D. Chen, Ting-Yu Horodniceanu, Erica G. Kluetz, Paul G. |
author_sort | Murugappan, Meena N. |
collection | PubMed |
description | PURPOSE: The objective of this retrospective study was to determine the feasibility of measuring frailty using patient responses to relevant EORTC QLQ-C30 items as proxy criteria for the Fried Frailty Phenotype, in a cohort of patients with Relapsed/Refractory Multiple Myeloma (RRMM). METHODS: Data were pooled from nine Phase III randomized clinical trials submitted to the FDA for regulatory review between 2010 and 2021, for the treatment of RRMM. Baseline EORTC QLQ-C30 responses were used to derive a patient-reported frailty phenotype (PRFP), based on the Fried definition of frailty. PRFP was assessed for internal consistency reliability, structural validity, and known groups validity. RESULTS: This study demonstrated the feasibility of adapting patient responses to relevant EORTC QLQ-C30 items to serve as proxy Fried frailty criteria. Selected items were well correlated with one another and PRFP as a whole demonstrated adequate internal consistency reliability and structural validity. Known groups analysis demonstrated that PRFP could be used to detect distinct comorbidity levels and distinguish between different functional profiles, with frail patients reporting more difficulty in walking about, washing/dressing, and doing usual activities, as compared to their pre-frail and fit counterparts. Among the 4928 patients included in this study, PRFP classified 2729 (55.4%) patients as fit, 1209 (24.5%) as pre-frail, and 990 (20.1%) as frail. CONCLUSION: Constructing a frailty scale from existing PRO items commonly collected in cancer trials may be a patient-centric and practical approach to measuring frailty. Additional psychometric evaluation and research is warranted to further explore the utility of such an approach. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11136-023-03390-5. |
format | Online Article Text |
id | pubmed-10025057 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-100250572023-03-21 Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma Murugappan, Meena N. King-Kallimanis, Bellinda L. Bhatnagar, Vishal Kanapuru, Bindu Farley, Joel F. Seifert, Randall D. Stenehjem, David D. Chen, Ting-Yu Horodniceanu, Erica G. Kluetz, Paul G. Qual Life Res Article PURPOSE: The objective of this retrospective study was to determine the feasibility of measuring frailty using patient responses to relevant EORTC QLQ-C30 items as proxy criteria for the Fried Frailty Phenotype, in a cohort of patients with Relapsed/Refractory Multiple Myeloma (RRMM). METHODS: Data were pooled from nine Phase III randomized clinical trials submitted to the FDA for regulatory review between 2010 and 2021, for the treatment of RRMM. Baseline EORTC QLQ-C30 responses were used to derive a patient-reported frailty phenotype (PRFP), based on the Fried definition of frailty. PRFP was assessed for internal consistency reliability, structural validity, and known groups validity. RESULTS: This study demonstrated the feasibility of adapting patient responses to relevant EORTC QLQ-C30 items to serve as proxy Fried frailty criteria. Selected items were well correlated with one another and PRFP as a whole demonstrated adequate internal consistency reliability and structural validity. Known groups analysis demonstrated that PRFP could be used to detect distinct comorbidity levels and distinguish between different functional profiles, with frail patients reporting more difficulty in walking about, washing/dressing, and doing usual activities, as compared to their pre-frail and fit counterparts. Among the 4928 patients included in this study, PRFP classified 2729 (55.4%) patients as fit, 1209 (24.5%) as pre-frail, and 990 (20.1%) as frail. CONCLUSION: Constructing a frailty scale from existing PRO items commonly collected in cancer trials may be a patient-centric and practical approach to measuring frailty. Additional psychometric evaluation and research is warranted to further explore the utility of such an approach. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11136-023-03390-5. Springer International Publishing 2023-03-20 /pmc/articles/PMC10025057/ /pubmed/36935467 http://dx.doi.org/10.1007/s11136-023-03390-5 Text en © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Murugappan, Meena N. King-Kallimanis, Bellinda L. Bhatnagar, Vishal Kanapuru, Bindu Farley, Joel F. Seifert, Randall D. Stenehjem, David D. Chen, Ting-Yu Horodniceanu, Erica G. Kluetz, Paul G. Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma |
title | Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma |
title_full | Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma |
title_fullStr | Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma |
title_full_unstemmed | Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma |
title_short | Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma |
title_sort | measuring frailty using patient-reported outcomes (pro) data: a feasibility study in patients with multiple myeloma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025057/ https://www.ncbi.nlm.nih.gov/pubmed/36935467 http://dx.doi.org/10.1007/s11136-023-03390-5 |
work_keys_str_mv | AT murugappanmeenan measuringfrailtyusingpatientreportedoutcomesprodataafeasibilitystudyinpatientswithmultiplemyeloma AT kingkallimanisbellindal measuringfrailtyusingpatientreportedoutcomesprodataafeasibilitystudyinpatientswithmultiplemyeloma AT bhatnagarvishal measuringfrailtyusingpatientreportedoutcomesprodataafeasibilitystudyinpatientswithmultiplemyeloma AT kanapurubindu measuringfrailtyusingpatientreportedoutcomesprodataafeasibilitystudyinpatientswithmultiplemyeloma AT farleyjoelf measuringfrailtyusingpatientreportedoutcomesprodataafeasibilitystudyinpatientswithmultiplemyeloma AT seifertrandalld measuringfrailtyusingpatientreportedoutcomesprodataafeasibilitystudyinpatientswithmultiplemyeloma AT stenehjemdavidd measuringfrailtyusingpatientreportedoutcomesprodataafeasibilitystudyinpatientswithmultiplemyeloma AT chentingyu measuringfrailtyusingpatientreportedoutcomesprodataafeasibilitystudyinpatientswithmultiplemyeloma AT horodniceanuericag measuringfrailtyusingpatientreportedoutcomesprodataafeasibilitystudyinpatientswithmultiplemyeloma AT kluetzpaulg measuringfrailtyusingpatientreportedoutcomesprodataafeasibilitystudyinpatientswithmultiplemyeloma |